Clinical trials: Locally Advanced Basal Cell Carcinoma
- Condition Locally Advanced Basal Cell Carcinoma
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Basal Cell Carcinoma
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
- Trial name
- BOLT (NCT01327053)
- Testing
- LDE225
- Where
- 62 sites in United States, Australia and 10 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Basal Cell
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic…
- Trial name
- NCT03897036
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Senhwa Biosciences, Inc.
Basal Cell Carcinoma
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma.
- Trial name
- NCT01367665
- Testing
- vismodegib
- Where
- 181 sites in Argentina, Australia and 35 more
- Volunteers
- 1,232 people
- Sponsor
- Hoffmann-La Roche
Solid Cancers
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.
- Trial name
- NCT00968981
- Testing
- GDC-0449
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.